论文信息 - A phase II study of YM155 administered as 168 hour continuous infusion in stage IV and unresectable stage III melanoma. - 字舞流文

A phase II study of YM155 administered as 168 hour continuous infusion in stage IV and unresectable stage III melanoma.

J. Kirkwood | K. Lewis | W. Samlowski | L. Cranmer | E. Whitman | R. Gonzales | P. Bartels | D. Lawson | D. Alexandrescu | A. Keating | J. Catlett | T. Drake